Defects in TLR3 expression and RNase L activation lead to decreased MnSOD expression and insulin resistance in muscle cells of obese people

O Fabre1, C Breuker1,2, C Amouzou1,3, T Salehzade1, M Kitzmann4, J Mercier1,3 and C Bisbal1,5

Obesity is associated with chronic low-grade inflammation and oxidative stress that blunt insulin response in its target tissues, leading to insulin resistance (IR), which is a central determinant of type 2 diabetes (T2D) pathogenesis. I Nevertheless, in about 30% of obese individuals, insulin sensitivity is preserved, and the mechanisms allowing these obese people to stay metabolically healthy being not yet clearly understood. Since the 50s, several studies have led to develop the idea that IR is a major consequence of the establishment of a chronic low-grade inflammatory state and oxidative stress. Excess of saturated free fatty acids (FFA) overly activates toll-like receptors (TLR), that leads to the local activation of innate immune response. It results in production and release of numerous cytokines such as type I interferons (IFN), interleukin (IL)-1β, IL-6 and tumor necrosis factor α (TNFα) and chemokines such as monocyte chemoattractant protein-1 (MCP-1), which activate inflammation and oxidative stress. However, the specific mechanisms linking TLR activation, inflammation, oxidative stress and defect in insulin sensitivity have been only partially characterized. Inflammation induces the expression and the activation of inflammatory kinases, such as c-Jun N-terminal kinase (JNK), c-Fos, proto-oncogene c-jun (JUN), extracellular signal-regulated kinases (ERK1/2), and stress-activated proteins kinase (SAPK) and phosphatidylinositol-3-kinase (PI3K). Hence, we explored the role of the latent endoribonuclease (RNase L) in skeletal muscle cells. RNase L is a regulator of innate immunity, of double-stranded RNA sensors and of toll-like receptor (TLR) 4 signaling. It is regulated during inflammation by interferons and its activity is dependent on its binding to 2-5A, an oligoadenylate synthesized by oligoadenylate synthetases (OAS). Increased expression of RNase L or downregulation of its inhibitor (RLI) improved insulin response in mouse myogenic C2C12 cells and in primary human myotubes from normal-weight subjects treated with palmitate, a saturated free fatty acid (FFA) known to induce inflammation and oxidative stress via TLR4 activation. While RNase L and RLI levels remained unchanged, OAS level was decreased in primary myotubes from insulin-resistant obese subjects (OB-IR) compared with myotubes from insulin-sensitive obese subjects (OB-IS). TLR3 and mitochondrial manganese superoxide dismutase (MnSOD) were also underexpressed in OB-IR myotubes. Activation of RNase L by 2-5A transfection allowed to restore insulin response, OAS, MnSOD and TLR3 expression in OB-IR myotubes. Due to low expression of OAS, OB-IR myotubes present a defect in RNase L activation and TLR3 regulation. Consequently, MnSOD level is low and insulin sensitivity is reduced. These results support that RNase L activity limits FFA/obesity-induced impairment of insulin response in muscle cells via TLR3 and MnSOD expression.

Cell Death and Disease (2014) 5, e1136; doi:10.1038/cddis.2014.104; published online 20 March 2014

Subject Category: Immunity

OPEN

Citation: Cell Death and Disease (2014) 5, e1136; doi:10.1038/cddis.2014.104
© 2014 Macmillan Publishers Limited All rights reserved 2041-4889/14

www.nature.com/cddis

Received 06.9.13; revised 12.2.14; accepted 13.2.14; Edited by M Federici
kinases/stress-activated protein kinases (JNK/SAPK) and double-stranded RNA-dependent protein kinase (PKR), which both phosphorylate insulin receptor substrate 1 (IRS1) on serine residues, thus disrupting insulin signaling. Moreover, these kinases activate another one, the inhibitor of 
\[ \kappa B (I\kappa B) \text{ kinase (IKK)}, \]
or directly phosphorylate I\kappa B, leading to activation of transcriptional nuclear factor \[ \kappa B (NF-\kappa B) \]
and expression of inflammatory genes.

In parallel, chronic FFA exposure is associated with increased reactive oxygen species (ROS) production (the main source being the mitochondria), through a TLR4-dependent mechanism that also involves innate immunity response and the release of pro-inflammatory cytokines including regulation of insulin signal transduction. Indeed, small amount of \[ \text{H}_2\text{O}_2 \]
is essential for many biological processes such as signaling cascade via tyrosine phosphorylation (e.g., insulin receptor, IRS1) or serine phosphorylation (protein kinase B (PKB)/Akt). If ROS are indispensable for the proper insulin response, their excess may however cause its disruption and contribute to IR and T2D, in particular because they lead to JNK activation. Therefore, ROS level must be tightly regulated. Pro-oxidants are naturally neutralized or detoxified by enzymes such as superoxide dismutases (SOD), glutathione peroxidases (GPx) and catalase, ‘oxidative stress’ resulting from an imbalance between ROS generation and anti-oxidant defenses.

Innate immunity, inflammation and oxidative stress processes are finely controlled by the induction of negative regulators to avoid unchecked immune reactions. IFN\( \alpha \) have an important role in the balance between activation and inhibition of immune responses, particularly through their anti-inflammatory properties such as inhibition of TNF\( \alpha \) and regulation of IL-10 production. The mechanism of this positive effect of IFN\( \alpha \) on insulin signaling has not yet been studied in depth.

The latent endoribonuclease (RNase L) is an essential actor of innate immunity and its activity is regulated by IFN\( \alpha \). During inflammation, the induction of its activity is essential for TLR4 signal transduction and for activation of double-stranded RNA sensors such as retinoic acid-inducible gene-1 (RIG-1) and melanoma differentiation-associated gene 5 (MAD5). RNase L activity is strictly dependent on its binding by small oligoadenylates, the 2-5A, which are synthesized by the 2-5A oligoadenylate synthetases (OAS), OAS1 and OAS2. OAS expression is also induced by IFN\( \alpha \). During inflammation, RNase L, when activated by 2-5A, cleaves single-stranded RNA at UpNp sequences during their translation, inhibiting protein synthesis. Via their secondary structures, these cleaved mRNA could also themselves regulate another RNA sensor pathway initiated by TLR3 activation. TLR3 activation leads to the synthesis of IFN-stimulated genes (ISG) such as OAS genes, thus to 2-5A synthesis. The 2-5A activate RNase L, leading to the amplification of TLR3 signaling. Moreover, IFN\( \alpha \), in turn, induce TLR3 expression in a positive amplification loop. RNase L activity is negatively regulated by RNase L inhibitor/ATP-binding cassette sub-family E member 1 (RLI/ABCE1). We previously demonstrated the major role of RNase L and RLI in lipids accumulation, cell fate and insulin response during myogenesis and adipogenesis via regulation of MyoD and C/EBP (CCAAT-enhancer-binding protein)-homologous protein 10 (CHOP10) mRNA expression.

Skeletal muscle is an essential organ for insulin action and glucose metabolism, and is the primary site of peripheral IR development. It is well documented that elevation of plasma FFA is currently associated with obesity and causes inflammation, oxidative stress and IR in skeletal muscle. The current study was performed to investigate the implication of RNase L/RLI in FFA-induced IR in skeletal muscle cells during obesity. Our results show that RNase L has an important role in maintaining insulin response during inflammation in mouse and human muscle cells. Myotubes from obese insulin-resistant (OB-IR) individuals, when compared with those from obese insulin-sensitive (OB-IS) individuals, are characterized by a lower expression of the enzymes manganese SOD (MnSOD) and OAS. Cell transfection with 2-5A allows to restore insulin response as well as MnSOD expression in OB-IR myotubes. Moreover, investigating the mechanism by which RNase L regulates insulin response led us to demonstrate that reduced expression of MnSOD and OAS is linked to low level of TLR3. We identify here a mechanism regulated by inflammation which allows maintenance of insulin response via TLR3 regulation and accounts for the difference between insulin-sensitive and insulin-resistant obese people’s muscle.

**Results**

**RNase L limits deleterious effect of palmitate on insulin signaling in mouse myogenic cells.** To determine the impact of RNase L/RLI expression on insulin signaling during inflammation, we evaluated insulin response in C2C12-derived mouse myogenic cells expressing different levels of RNase L or RLI, after FFA treatment. The saturated FFA palmitate was used here to mimic the effect of elevated circulating FFA, known to induce an acute pro-inflammatory response via TLR pathway in obesity. As previously described and shown in Figure 1a, RNase L and RLI expression was significantly increased in C2-RNaseL+ cells (\( P = 0.028 \)) and C2-RLI (\( P = 0.024 \)), respectively, compared with C2-RNaseL control cells.

Without induction of inflammation, insulin response was totally abolished in cells overexpressing RLI (C2-RLI), as shown by no increase in P-Akt/Akt expression rate following insulin stimulation, while Akt phosphorylation was induced in the two other C2C12-derived cell lines (Figure 1b). In basal conditions, we observed no any difference in insulin response between cells overexpressing RNase L (C2-RNaseL+) and C2-RNasel. This could be explained on account of the fact that, without inflammation induction, insulin response was already high in C2-RNasel. On the other hand, palmitate treatment blunted insulin response in C2-RNaseL and C2-RNasel+, C2-RNaseL however maintaining a significantly higher level of P-Akt/Akt expression rate than...
C2-RNaseL (Figure 1b). As expected, there was no insulin-stimulated Akt phosphorylation in C2-RLI after palmitate exposure (Figure 1b).

Downregulation of RLI expression impacts palmitate-induced impairment of insulin response in myotubes from normal-weight subjects. Human primary myotubes obtained from skeletal muscle of normal-weight subjects were transfected with specific RNase L (Myo-siRNaseL) or RLI (Myo-siRLI) siRNA or with a non-specific siRNA (Myo-siControl) before palmitate treatment and/or insulin stimulation.

In Myo-siControl, palmitate treatment induced RNase L and RLI proteins expression without increasing RNase L or RLI mRNA levels (Figures 2a and b). This indicates that the induction of these proteins would be the result of a post-transcriptional regulatory mechanism such as increased protein translation, as yet demonstrated for RNase L.35 Both RNase L and RLI mRNA levels were significantly lower in Myo-siRNaseL (*P = 0.039) and Myo-siRLI (*P = 0.029), respectively, compared with Myo-siControl, demonstrating the effectiveness of siRNA degradation, that is, specific mRNA stability and mRNA translation.37

Palmitate treatment similarly impaired insulin signaling in Myo-siControl and Myo-siRNaseL, as shown by a relative fold expression of insulin-stimulated P-Akt/Akt rate inferior to 1 (0.75 ± 0.07 and 0.81 ± 0.10, respectively), while it was significantly maintained and even increased in Myo-siRLI (1.41 ± 0.30) (Figure 2c; *P = 0.032). The absence of RNase L siRNA effect on insulin response in Myo-siRNaseL could be explained by the fact that, at these concentrations of palmitate, inhibition of insulin response is yet maximal (compare insulin-stimulated P-Akt/Akt expression rate in cells transfected with Control and RNase L siRNA in Figure 2c).

OAS expression is impaired in human myotubes from OB-IR subjects and activation of RNase L with exogenous 2-5A allows to restore insulin response in OB-IR myotubes. As stated in Introduction, not all obese people develop IR. Our results indicating that RNase L/RLI could impact insulin response in muscle cells, prompted us to analyze their expression in primary myotubes from obese subjects divided into two groups, insulin-sensitive (OB-IS) and insulin-resistant (OB-IR), on the basis of their homeostasis model assessment of IR (HOMA-IR) index (Table 1). Accordingly with previous studies,38,39 insulin-stimulated P-Akt/Akt expression rate and glucose uptake level were significantly reduced, by 56% (Figure 3a; **P = 0.005) and
31% (Figure 3b; **P = 0.003), respectively, in OB-IR group compared with OB-IS. In an unexpected way, RNase L and RLI levels were similar in the two groups of obese subjects (Figure 3c).

However, OAS2 protein level was decreased by 69% in myotubes of OB-IR group compared with OB-IS (Figure 4a; *P = 0.045). We also evaluated OAS1 protein expression but failed to detect it. Moreover, OAS mRNA levels were also diminished in OB-IR group (Figure 4b; *P = 0.05). However, contrary to OAS2 mRNA, the inter-subject variability did not allow for demonstrating any significant difference in OAS1 mRNA expression between the two groups. We hypothesized that the decreased levels of OAS mRNA in OB-IR myotubes could be due to an increase in the suppressor of cytokine signaling 3 (SOCS3) expression, which is induced during inflammation and is known as an important negative regulator of OAS expression.40 However, we found no difference in SOCS3 expression between OB-IS and OB-IR groups (Figure 4c).

31% (Figure 3b; **P = 0.003), respectively, in OB-IR group compared with OB-IS. In an unexpected way, RNase L and RLI levels were similar in the two groups of obese subjects (Figure 3c).

Figure 2. Insulin response of normal-weight subjects’ myotubes after siRNA transfection and palmitate treatment. (a) Human myotubes were transfected with control siRNA (Myo-siControl) or specific siRNA against RLI (Myo-siRLI) or RNase L (Myo-siRNaseL) and were then incubated or not with palmitate. Total RNA were then extracted from siRNA-transfected cells to measure expression of RNase L and RLI mRNA by q-PCR. For each mRNA, the mean level of mRNA expression in Myo-siControl was set at 1. Error bars refer to the S.E.M. obtained from five samples issued from different donors. *P < 0.05 and **P < 0.01. (b) Human myotubes were siRNA-transfected and were then incubated or not with palmitate. RNase L and RLI proteins expression was assessed on total cellular extracts by western blotting. Membrane scans obtained from two different samples are presented in the figure. RNase L and RLI levels in Myo-siControl without palmitate treatment were set at 100%. Error bars refer to the S.E.M. obtained from five samples issued from different donors. *P < 0.05. (c) siRNA-transfected human myotubes were incubated or not with palmitate then stimulated or not with insulin. P-Akt and Akt proteins expression was assessed on total cellular extracts by western blotting. Membrane scans obtained from two different samples of each siRNA-transfected cell population are presented in the figure. Data are expressed relative to the fold induction of P-Akt/Akt protein level in each cell population with neither palmitate treatment nor insulin stimulation (basal response), which was set at 1. Error bars refer to the S.E.M. obtained from five samples issued from different donors. *P < 0.05.

Table 1. Clinical characteristics of obese subjects

| Group               | OB-IS (n = 7) | OB-IR (n = 8) |
|---------------------|---------------|---------------|
| Gender              | Male          | Male          |
| Age (years)         | 50.4 ± 2.9    | 51.6 ± 1.7    |
| Body mass index (kg/m²) | 32.6 ± 1.2    | 33.7 ± 0.9    |
| Body fat (%)        | 30.1 ± 1.4    | 32.0 ± 1.7    |
| Fasting blood glucose [G] (mM) | 5.32 ± 0.20   | 5.50 ± 0.15   |
| Fasting plasma insulin [I] (pU/ml) | 6.89 ± 0.68   | 16.66 ± 1.84** |
| HOMAIR              | 1.64 ± 0.19   | 4.08 ± 0.61*  |

Values are means ± S.E.M.
**P < 0.001 fasting plasma insulin level of OB-IR subjects compared with OB-IS subjects.
*P < 0.002 Homeostasis model assessment of insulin resistance index (HOMAIR = [I]x[G]/22.5) of OB-IR subjects compared with OB-IS subjects.
restored insulin response in OB-IR myotubes (Figures 4d and e). Important to note, 2-5A transfection also induced an increase of OAS1 and OAS2 mRNA expression in OB-IR myotubes, by 560 and 575%, respectively (Figure 4f; \( P = 0.047 \)), that cancelled out the significance of the difference in OAS2 mRNA expression between OB-IS and OB-IR groups.

RNase L regulates neither PKR and IκB expression, nor JNK and IRS1 (serine 312) phosphorylation. PKR has an important role in blunting insulin signaling during inflammation via IRS1 phosphorylation on serine residues, directly or indirectly by phosphorylating and activating JNK. Moreover, PKR also regulates IKK activation, leading to IκB degradation and NF-κB activation. On the other hand, it has been demonstrated that RNase L modulates PKR expression. However, we observed no difference in IκB, PKR, P-JNK/JNK and Ser312-P-IRS1/IRS1 expression levels between OB-IS and OB-IR groups (Figure 5). RNase L regulates MnSOD expression. During obesity, lipid overload causes oxidative stress by increasing ROS production and/or altering anti-oxidant defenses that can lead to muscle IR. We thus checked in OB-IS and OB-IR myotubes mRNA expression of several major anti-oxidant enzymes and of the transcriptional nuclear factor erythroid 2-related factor 2 (NRF2) that regulates their expression. Only MnSOD mRNA was significantly underexpressed, by 77%, in myotubes of OB-IR subjects compared with OB-IS (Figure 6a; \( P = 0.021 \)), which was confirmed at the protein level with 66% underexpression (Figure 6b, see white bars; \( P < 0.005 \)). Furthermore, RNase L activation with exogenous 2-5A significantly increased MnSOD mRNA expression, by 285% (Figure 6c; \( P = 0.004 \)), as well as MnSOD protein expression, by 176% (Figure 6b; \( P = 0.033 \)), in OB-IR myotubes, allowing to cancel out the significances between OB-IS and OB-IR groups. As we observed for OAS1 and OAS2 mRNA (Figure 4f), 2-5A transfection increased MnSOD mRNA level in OB-IS myotubes, this effect being here statistically significant. We assume that, even when MnSOD mRNA is highly expressed, overactivation of RNase L by exogenous 2-5A could lead to its induction. However, the level of MnSOD protein was not modified after 2-5A transfection in OB-IS myotubes as it was in OB-IR myotubes (Figure 6b), which could be indicative of a regulation of MnSOD expression by a post-transcriptional mechanism.
MnSOD is the mitochondrial SOD; however, its low expression in OB-IR myotubes does not seem due to a different mitochondrial mass between OB-IS and OB-IR myotubes, as we observed no variation in the expression of two other mitochondrial proteins: the mitochondrial uncoupling protein 3 (UCP3) and the subunit IV of cytochrome c oxidase (COX IV) (Figure 6d).

TLR3 expression is decreased in OB-IR myotubes. As RNase L activation by exogenous 2-5A restored the expression of MnSOD and OAS in OB-IR myotubes, we concluded that a common regulator of these proteins was affected in OB-IR myotubes contrary to OB-IS. An essential regulatory mechanism of MnSOD and OAS expression during inflammation and oxidative stress involves TLR3 activation. Indeed, previous studies have shown that TLR3 activation (i) protects cells against oxidative stress through the upregulation of MnSOD\textsuperscript{44,45} and (ii) induces IFN production and OAS expression after TLR3 recognition of small mRNA fragments. We thus measured TLR3 mRNA expression in OB-IS and OB-IR myotubes: unlike TLR4, TLR3 mRNA was significantly underexpressed, by 72%, in OB-IR myotubes compared with OB-IS (Figure 6e; \( *P < 0.05 \)). Finally, as OAS2 and MnSOD mRNA, 2-5A transfection induced a significant increase, by 195%, of TLR3 mRNA expression in OB-IR myotubes (Figure 6f; \( *P < 0.05 \)), allowing to cancel out the significance between OB-IS and OB-IR groups.

Discussion

Obesity has an undeniable impact on health by promoting the occurrence of chronic diseases including T2D.\textsuperscript{1} Although it is known that IR appears several decades before the onset of
T2D, the pathophysiological mechanisms involved in the development of the disease are still not fully understood. Importantly, it is difficult to explain why a subset (30%) of obese individuals seems preserved from IR and other metabolic disorders during weight gain.2,3 The identification of the pathways implicated in the regulation of insulin response in these two groups of obese people is a key issue to understand the pathogenesis of IR.

Skeletal muscle, due to its mass, is an essential organ in maintenance of glycemic homeostasis and has a key role in IR and T2D pathogenesis.31 So, understanding the cellular mechanisms that regulate insulin response in muscle of obese people is of primary importance and could help to understand the differences between insulin-sensitive and insulin-resistant subjects.

During the last decade, the central role played by innate immunity and TLR activation in the pathogenesis of IR has been demonstrated. RNase L, which is an essential component of the innate immune response, is activated through IFN-γ production following TLR 3/4 activation and could amplify TLR activation.20–22 RNase L activity is regulated by its binding to 2-5A, which is synthesized by OAS, and by RLI. We recently demonstrated that insulin response was impaired in RNase L−/−-MEF and partially restored after re-introduction of RNase L expression in these cells.29 These findings incited us to study the potential role of RNase L/RLI in regulation of insulin response, at muscle level.

Here, our results reveal that RNase L activity allows for maintaining an insulin response during FFA-induced inflammation in mouse and human myotubes. Indeed, in our two models, the impairment of insulin response induced by palmitate treatment, which mimics inflammation observed during obesity, was limited in cells expressing higher level of RNase L/RLI ratio (C2-RNaseL−/− and Myo-siRLI) compared with respective control cells. Insulin-stimulated phosphorylation of Akt was even improved by RLI siRNA transfection in palmitate-treated human myotubes, showing the importance of RNase L activity to limit FFA deleterious effect on insulin response.

As stated above, one intriguing and still not explained fact is the existence of insulin-sensitive individuals among obese people. If RNase L and RLI levels were similar in two groups of obese individuals with different insulin sensitivity states, then the levels of OAS2 protein and OAS1 and OAS2 mRNA were lower in OB-IR myotubes. 2-5A level could thus be the limiting factor for a correct insulin response. Indeed, 2-5A transfection restored insulin-stimulated P-Akt/Akt and glucose uptake levels in OB-IR myotubes to comparable levels of those in OB-IS myotubes. These results confirm that low 2-5A production, due to decreased expression of OAS, leads to underactivation of RNase L and impaired insulin response in OB-IR myotubes. Our findings underline the importance of RNase L activity in the development of IR in skeletal muscle during obesity.

The next objectives of this study were to determine how RNase L can regulate insulin response and why OAS levels are low in OB-IR myotubes. One of the known targets of RNase L is another mediator of innate immunity, the enzyme PKR.43 PKR is activated in tissues of obese mice and, consequently, can directly or indirectly (through JNK activation) induce negative phosphorylation of IRS1 as well as activation of IKK. As a result, these two activated pathways lead to the disruption of insulin response combined with the synthesis of inflammatory cytokines.8,9 However, we neither found any significant variation of PKR and IκB expression levels, nor of P-JNK/JNK and Ser312P-IRS1/IRS1 expression rates between OB-IS and OB-IR myotubes. According to these observations, the mechanism by which RNase L activity allows for maintaining insulin response in myotubes during obesity does not depend on PKR regulation.

As oxidative stress is induced during obesity and has an important role in IR development, we checked the expression levels of several enzymes implicated in the anti-oxidant defense. Only MnSOD was weakly expressed in OB-IR myotubes, that does not seem related to a lower mitochondria mass, as attested by the similar levels of two other mitochondrial proteins (UCP3 and COX IV) in OB-IS and OB-IR myotubes. MnSOD expression is necessary to maintain insulin sensitivity during obesity. Indeed, not only its expression is upregulated by treatments that improve insulin sensitivity,46,47 but muscle transfection with plasmid allowing for increased MnSOD expression in vivo preserves insulin response during high-fat diet-induced obesity.48 We hypothesize that the high MnSOD expression observed in OB-IS myotubes may (i) counteract the highly toxic superoxide anion (O₂⁻) produced in excess by mitochondria during lipid overload49 and (ii) rise H₂O₂ production that is essential to maintain insulin sensitivity.49,50 As an explanation of MnSOD underexpression in OB-IR myotubes, we identified a defect in TLR3 expression, which is known to protect against inflammation and oxidative stress in different models.51–54

**Figure 5** Analysis of PKR and IκBα expression and JNK and IRS1 phosphorylation in obese insulin-sensitive and insulin-resistant subjects’ myotubes. Myotubes of OB-IS (n = 7) and OB-IR (n = 8) subjects were collected and expression of IκBα, PKR, P-JNK, JNK, Ser312P-IRS1 and IRS1 proteins was assessed on total cellular extracts by western blotting. Membrane scans obtained and T2D pathogenesis. 31 So, understanding the cellular maintenance of glycemic homeostasis and has a key role in IR response in these two groups of obese people is a key issue to understand the pathogenesis of IR.

2-5A, which is synthesized by OAS, and by RLI. We recently demonstrated that insulin response was impaired in RNase L−/−-MEF and partially restored after re-introduction of RNase L expression in these cells.29 These findings incited us to study the potential role of RNase L/RLI in regulation of insulin response, at muscle level.

Here, our results reveal that RNase L activity allows for maintaining an insulin response during FFA-induced inflammation in mouse and human myotubes. Indeed, in our two models, the impairment of insulin response induced by palmitate treatment, which mimics inflammation observed during obesity, was limited in cells expressing higher level of RNase L/RLI ratio (C2-RNaseL−/− and Myo-siRLI) compared with respective control cells. Insulin-stimulated phosphorylation of Akt was even improved by RLI siRNA transfection in palmitate-treated human myotubes, showing the importance of RNase L activity to limit FFA deleterious effect on insulin response.

As stated above, one intriguing and still not explained fact is the existence of insulin-sensitive individuals among obese people. If RNase L and RLI levels were similar in two groups of obese individuals with different insulin sensitivity states, then the levels of OAS2 protein and OAS1 and OAS2 mRNA were lower in OB-IR myotubes. 2-5A level could thus be the limiting factor for a correct insulin response. Indeed, 2-5A transfection restored insulin-stimulated P-Akt/Akt and glucose uptake levels in OB-IR myotubes to comparable levels of those in OB-IS myotubes. These results confirm that low 2-5A production, due to decreased expression of OAS, leads to underactivation of RNase L and impaired insulin response in OB-IR myotubes. Our findings underline the importance of RNase L activity in the development of IR in skeletal muscle during obesity.

The next objectives of this study were to determine how RNase L can regulate insulin response and why OAS levels are low in OB-IR myotubes. One of the known targets of RNase L is another mediator of innate immunity, the enzyme PKR.43 PKR is activated in tissues of obese mice and, consequently, can directly or indirectly (through JNK activation) induce negative phosphorylation of IRS1 as well as activation of IKK. As a result, these two activated pathways lead to the disruption of insulin response combined with the synthesis of inflammatory cytokines.8,9 However, we neither found any significant variation of PKR and IκB expression levels, nor of P-JNK/JNK and Ser312P-IRS1/IRS1 expression rates between OB-IS and OB-IR myotubes. According to these observations, the mechanism by which RNase L activity allows for maintaining insulin response in myotubes during obesity does not depend on PKR regulation.

As oxidative stress is induced during obesity and has an important role in IR development, we checked the expression levels of several enzymes implicated in the anti-oxidant defense. Only MnSOD was weakly expressed in OB-IR myotubes, that does not seem related to a lower mitochondria mass, as attested by the similar levels of two other mitochondrial proteins (UCP3 and COX IV) in OB-IS and OB-IR myotubes. MnSOD expression is necessary to maintain insulin sensitivity during obesity. Indeed, not only its expression is upregulated by treatments that improve insulin sensitivity,46,47 but muscle transfection with plasmid allowing for increased MnSOD expression in vivo preserves insulin response during high-fat diet-induced obesity.48 We hypothesize that the high MnSOD expression observed in OB-IS myotubes may (i) counteract the highly toxic superoxide anion (O₂⁻) produced in excess by mitochondria during lipid overload49 and (ii) rise H₂O₂ production that is essential to maintain insulin sensitivity.49,50 As an explanation of MnSOD underexpression in OB-IR myotubes, we identified a defect in TLR3 expression, which is known to protect against inflammation and oxidative stress in different models.51–54
The concomitant significant increase in MnSOD and TLR3 expression following 2-5A transfection would be in favor of our hypothesis. We propose that, during FFA-induced inflammation, RNase L is activated by the OAS-synthesized 2-5A. RNase L then cleaves mRNA in smaller RNA, which in turn could activate TLR3 pathway. This activation induces the expression of the anti-oxidant enzyme MnSOD and numerous ISG among which the OAS genes. This secondary activation of OAS by cleaved mRNA entails increased 2-5A production that all the more activates RNase L. It then creates an amplification loop that leads to higher activation of TLR3 and higher levels of OAS and MnSOD, as observed in myotubes from OB-IS subjects. By controlling H₂O₂ level, MnSOD allows for maintaining Akt phosphorylation and glucose uptake, even when excessive ROS are produced. At the contrary, myotubes of OB-IR subjects express very low level of TLR3 that prevents this amplification loop to setting up. The consecutive underexpression of OAS and MnSOD thus causes the inhibition of insulin response in myotubes of OB-IR subjects. The global mechanism we identified here is recapitulated by a scheme, in Figure 7.

Materials and Methods

Mouse myogenic cells. For conditional expression of RNase L, human complementary DNA (cDNA) was cloned in the LacSwitch II inducible mammalian expression system (Stratagene, Massy, France). The C2C12 clone in which
RNase L is conditionally expressed (C2-RNaseL) and C2-RLI cells that overexpress RL1 were previously described. For induction of RNase L (C2-RNaseL⁻), differentiated C2-RNaseL cells were incubated with isopropyl-D-thiogalactopyranoside (IPTG) (2 mM) during 6 h.

Human cells. Primary human skeletal muscle cells from five normal-weight (19 < body mass index (BMI) < 25 kg/m²) subjects were provided by the Agence Française contre les Myopathies (AFM), in accordance with the French and European legislations.

The present study involved 15 non-diabetic obese (BMI > 30 kg/m²) subjects, all with no personal or familial history of diabetes. Their HOMA IR index, which is frequently used in routine clinical medicine to estimate insulin sensitivity state, was evaluated to separate them into insulin-sensitive (OB-IS: HOMA IR < 1) and insulin-resistant (OB-IR: HOMA IR > 1) groups (a subject whom the HOMA IR index is superior to 3 is conventionally considered as insulin-resistant). The characteristics of these subjects are presented in Table 1. Skeletal muscle cells were obtained from biopsies in the vastus lateralis. This experimental protocol was approved by the local Ethic Committee (03/10/GESE, Montpellier, France) and informed written consent was obtained from all the participants.

Myoblasts isolation, purification and culture were performed as described by Barro et al. Cells between passages 2 and 6 were used for all the experiments.

Cell differentiation. At confluence, C2C12-derived cells and human myoblasts were switched to muscle differentiation medium (Dulbecco’s modified eagle medium (DMEM; Lonza, Basel, Switzerland) supplemented with 2% (V/V) FCS (PAN Biotech, Duscher, Brumath, France)) for 5 days.

Cell transfection. Human cells were transfected 4 days after induction of muscle differentiation. siRNA were transfected with HiPerFect (Qiagen, Courtabœuf, France) following the manufacturer’s instructions. Cells were incubated with siRNA for 8 h at 37 °C. siRNA sequences are indicated in Supplementary Table 1.

A non-stabilized non-modified 2-5A was enzymatically produced with double-stranded RNA-activated OAS from IFN/β-treated HeLa cells (500 U/ml) and was transfected at 10 nM final concentration with the Calcium Phosphate Transfection Kit (Sigma-Aldrich, Saint-Quentin Fallavier, France) following the manufacturer’s instructions. Cells were incubated for 6 h at 37 °C with 2-5A then total RNA were extracted as described in a following paragraph. RNase L activation by 2-5A was checked by controlling 28S and 18S specific cleavage as previously described (data not shown).

Induction of inflammation and insulin treatment. Four days after induction of differentiation, muscle cells were treated with palmitate, then insulin-stimulated and harvested. Lipid-containing media were prepared by conjugation of palmitate with FFA-free BSA (molar ratio palmitate/BSA = 2.5). Cells were incubated for 16 h at 37 °C with 750 μM palmitate. For insulin response, cells were treated with human insulin (1 nM) for 10 min at 37 °C.

Western-blot assay. Differentiated cells were washed and lysed in SDS-PAGE sample buffer (300 mM Tris (pH 8.9), 5% (V/W) SDS, 750 mM β-mercaptoethanol, 20% (V/V) glycerol, bromophenol blue). From these cellular extracts, proteins were fractionated, electrophoretically transferred onto nitrocellulose membrane to be then incubated with the different antibodies and analyzed with the Odyssey Infrared Imaging System LI-COR (Biosciences, ScienceTec, Courtabœuf, France) as previously described. We used primary antibodies against the following proteins: Phospho-Akt (Ser473), Akt, IκBα, PKR, Phospho-SAPK/JNK (Thr183/Tyr185), SAPK/JNK, IRS1, SOCS3, COX IV (nine from Cell Signaling, Ozyme, Saint-Quentin Yvelines, France), RNase L (mouse), ABCE1 (mouse), OAS2 (three from Santa Cruz, Tebu-Bio, Le Perray en Yvelines, France), α-tubulin, UCP3 (both from Sigma-Aldrich), RNase L (human), Phospho-IRS1

**Figure 7** Role of RNase L and TLR3 activation during inflammation in insulin response of obese people’s myotubes. During obesity, chronic lipid overload triggers the development of global inflammation and oxidative stress, which are particularly deleterious for metabolic tissues such as skeletal muscle. RNase L, which is activated by the 2-5A synthesized by the OAS, cleaves mRNA, which in turn could activate TLR3 pathway. This activation allows the expression of MnSOD and of numerous ISG among which the OAS genes. The secondary activation of the OAS induced by cleaved mRNA leads to increased 2-5A production that all the more activates RNase L. It then creates an amplification loop that induces high levels of OAS and MnSOD expression in myotubes from insulin-sensitive obese people. By controlling H₂O₂ levels, high expression of MnSOD allows for maintaining Akt phosphorylation and glucose uptake, even when excessive ROS are produced. At the contrary, myotubes from obese insulin-resistant people express very low level of TLR3 that prevents this amplification loop to setting up. The consecutive underexpression of OAS and MnSOD is thus responsible for oxidative stress development and inhibition of insulin response. IR, insulin receptor; MyD88, myeloid differentiation primary response gene 88
Glucose uptake. After 10 min incubation at 37 °C with or without 1 mM insulin, differentiated human cells were incubated for 30 min at 37 °C with 300 μM 6-(7-nitrobenz-2-oxa-1,3-diazole-4-yl) amino]-2-deoxy-glucose (6-NBDG). Molecular Probes, Thermo Fisher Scientific, Illkirch Graffenstaden, France) in a glucose-free medium (Invitrogen, Life Technologies, Saint Aubin, France), as previously described.29 Fluorescence intensity of 6-NBDG was measured at 540 nm wavelength (465 nm excitation wavelength) with an Infinite 200PRO TECAN (Lyon, France). Fluorescence values were normalized by cell number.

Statistical analysis. Values represented in the graphs are means; error bars refer to the standard errors of the mean (S.E.M.). Statistical analyses were performed using the SigmaStat software (RITME Informatique, Paris, France). Statistical significance was determined by using a one-way analysis of variance (ANOVA) followed up with all pairwise multiple comparison procedures (Holm–Sidak method) to compare values from two different groups, or by an ANOVA followed up with all pairwise multiple comparison procedures (Tukey’s HSD test) to compare values from the same group before and after treatment. Two groups were considered as statistically significantly different for \( P < 0.05 \).

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements

This work was supported by grants from Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Montpellier 1 (UM1) and Centre Hospitalier Régional Universitaire (CHRU) Montpellier. OF and CA were recipient of a Ministère de l’Enseignement Supérieur et de la Recherche (MESR) fellowship.

1. Kahn SE, Hull RL,utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840–846.
2. Buher M. Are there still healthy obese patients? Curr Opin Endocrinol Diabetes Obes 2012; 19: 341–346.
3. Kurelis AD, Faraj M, Bastard JP, Le Marchand-Brustel Y, Tanti JF, Rudich A et al. Differential effects of IRS1 phosphorylated on Ser307 or Ser323 in the induction of insulin resistance by oxidative stress. Diabetologia 2006; 49: 2463–2473.
4. Vinayagamoorthy R, Bobby Z, Sridhar MG. Antioxidants preserve rodox balance and inhibit c-Jun-N-terminal kinase pathway while improving insulin signaling in fat-fed rats: evidence for the role of oxidative stress on IRS-1 serine phosphorylation and insulin resistance. J Endocrinol 2008; 197: 287–296.
5. Choubey D, Moudgil KD. Interferons in autoimmune and inflammatory diseases: regulation and roles. J Interferon Cytokine Res 2011; 31: 857–885.
6. Bissel C, Silverman RH. Diverse functions of RNase L and implications in pathology. Biochimie 2007; 89: 789–798.
7. Malathi K, Dong B, Gale M Jr., Silverman RH. Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature 2007; 448: 816–819.
8. Li XL, Ezele HJ, Kang TJ, Zhang X, Sheney KA, Harro J et al. An essential role for the antiviral endoribonuclease, RNase L, in antimalarial immunity. Proc Natl Acad Sci USA 2011; 108: 20416–20421.
9. Le Roy F, Salehzada T, Bissel C, Dougherty JP, Pelz SW. A newly discovered function for RNase L in regulating translation termination. Nat Struct Mol Biol 2005; 12: 505–512.
10. Kanki K, Ni H, Capodici J, Lamphier M, Weissman D. mRNAs is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2006; 281: 4959–4969.
11. Fabre O, Salehzada T, Lambert K, Bos Secq Y, Zhou A, Mercier J et al. RNase L controls terminal adipecide differentiation, lipid storage and insulin sensitivity via CHOP10 mRNA regulation. Cell Death Differ 2012; 19: 1470–1481.
12. Salehzada T, Cambier L, Vu Th N, Manchon L, Regnier L, Bissel C. Endoribonuclease L (RNase L) regulates the myogenic and adipogenic potential of myogenic cells. PLoS ONE 2009; 4: e7563.
38. Jackson S, Bagstaff SM, Lynn S, Yeaman SJ, Turnbull DM, Walker M. Decreased insulin responsiveness of glucose uptake in cultured human skeletal muscle cells from insulin-resistant non-diabetic relatives of type 2 diabetic families. Diabetes 2000; 49: 1169–1177.

39. Krook A, Roth RA, Jiang X, Zierath JR, Walberg-Henriksson H. Insulin-stimulated Akt kinase activity is reduced in skeletal muscle from NIDDM subjects. Diabetes 1998; 47: 1281–1286.

40. Viotti G, Sorensen AS, Kopp F, Zitzmann K, Cengic N, et al. SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2,5-OAS and MxA. Biochem Biophys Res Commun 2004; 320: 1007–1014.

41. Jorgensen SB, O'Neill HM, Sylow L, Honeyman J, Hewitt KA, Palanivel R et al. Deletion of skeletal muscle SOCS3 prevents insulin resistance in obesity. Diabetes 2013; 62: 56–64.

42. Yang Z, Hulver M, McMillan RP, Cai L, Kershaw EE, Yu L et al. Overexpression of manganese superoxide dismutase ameliorates high-fat diet-induced obesity men. Proc Natl Acad Sci USA 2009; 106: 8665–8670.

43. Khabar KS, Siddiqui YM, al-Zoghaibi F, al-Haj L, Dhalla M, Zhou A et al. Myoblasts protective role for Toll-like receptor 3 in the arterial wall. Proc Natl Acad Sci USA 2011; 108: 2372–2377.

44. Borysiewicz E, Doppalapudi S, Kirschman LT, Konat GW. TLR3 ligation protects human astrocytes against oxidative stress. J Neuroimmunol 2013; 255: 54–59.

45. Rakkola R, Matikainen S, Nyman TA. Proteome analysis of human macrophages reveals the upregulation of manganese-containing superoxide dismutase after toll-like receptor activation. PloS ONE 2012; 7: e47493.

46. Qiu X, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces oxidative stress and obesity in mice overexpressing cellular glutathione peroxidase. Proc Natl Acad Sci USA 2010; 107: 662–667.

47. Samjoo IA, Safdar A, Hamadeh MJ, Raha S, Tamopolsky MA. The effect of endurance exercise on both skeletal muscle and systemic oxidative stress in previously sedentary obese men. Nutr Diabetes 2013; 3: e88.

48. Boden MJ, Brandon AE, Tid-Ang JD, Preston E, Wilks D, Stuart E et al. Overexpression of manganese superoxide dismutase ameliorates high-fat diet-induced insulin resistance in rat skeletal muscle. Am J Physiol Endocrinol Metab 2012; 303: E788–E796.

49. McClung JP, Roneyer CA, Mu W, Lisk DJ, Langlas P, Liu F et al. Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase. Proc Natl Acad Sci USA 2004; 101: 8852–8857.

50. Ristow M, Zarse K, Oberbach A, Kotting N, Birlinger M, Kienztopf M et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci USA 2009; 106: 8665–8670.

51. Babig M, Persoon-Deen C, Verwer RW, Meeuwsen S, Ravid R, Van Noort JM. Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators. Glia 2006; 53: 689–695.

52. Cole JE, Navin TJ, Cross AJ, Goodard ME, Alexopoulou L, Mitra AT et al. Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc Natl Acad Sci USA 2011; 108: 2372–2377.

53. Hoffeld J, Tepekozyu C, Kozaryn R, Urban P, Zacharowski K, Grimm M et al. Shockwave therapy differentially stimulates endothelial cells: implications on the control of inflammation via Toll-like receptor 3. Inflammation 2013; 37: 65–70.

54. Patel AK, Hackam AS. Toll-like receptor 3 (TLR3) protects retinal pigmented epithelium (RPE) cells from oxidative stress through a STAT3-dependent mechanism. Mol Immunol 2013; 54: 122–131.

55. Barro M, Camac G, Flavier S, Mercier J, Vassetzky Y, Laouedj-Chenivesse D. Myoblasts from affected and non-affected FSHD muscles exhibit morphological differentiation defects. J Cell Mol Med 2010; 14: 275–289.

56. Bayard B, Bilbali C, Silhol M, Cnockaert J, Huez G, Leblou B. Increased stability and antiviral activity of 2'-O-phosphorylated derivatives of (2'-5')oligoadenylate. Eur J Biochem 2014; 142: 291–298.

57. Rusch L, Zhou A, Silverman RH. Caspase-dependent apoptosis by 2',5'-oligoadenylate activation of RNase L is enhanced by IFN-beta. J Interferon Cytokine Res 2000; 20: 1091–1100.

58. Wreschner DH, James TC, Silverman RH, Kerr IM. Ribosomal RNA cleavage, nucleic acid activation and 2-SAMP(2'-5') in interferon-treated cells. Nucleic Acids Res 1981; 9: 1571–1581.

59. Wang X, Yu W, Nawaz A, Guan F, Sun S, Wang C. Palmitate induced insulin resistance by PKCtheta-dependent activation of mTOR/S6K pathway in C2C12 myotubes. Exp Clin Endocrinol Diabetes 2010; 118: 657–661.

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)